PMC:6640909 / 84971-85820 JSONTXT

{"project":"TEST0","denotations":[{"id":"31100109-214-221-7655","span":{"begin":714,"end":717},"obj":"[\"28007058\"]"},{"id":"31100109-124-131-7656","span":{"begin":844,"end":847},"obj":"[\"28009714\"]"}],"text":"11.4 Total artificial heart\nA certain percentage of patients require biventricular support with either BiVAD placement or implantation of a TAH. The 70-cc TAH (SynCardia Systems Inc., Tucson, AZ, USA) is currently the only Food and Drug Administration (FDA)-approved and Conformité Européenne (CE)-marked TAH licensed for bridge to transplant or destination therapy. However, this device is limited to patients with a larger chest cavity with adequate intrathoracic space to accommodate this device. The 50 cc-TAH (currently under investigation for FDA approval) is more appropriate for use in smaller patients, especially in complex cases who have had limited clinical options such as failing Fontan circulation [300]. Unsurprisingly, reported outcomes in patients ≤21 years supported with a TAH seem to be inferior to LVAD-only implantation [301]."}

{"project":"MyTest","denotations":[{"id":"31100109-28007058-28905715","span":{"begin":714,"end":717},"obj":"28007058"},{"id":"31100109-28009714-28905716","span":{"begin":844,"end":847},"obj":"28009714"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"11.4 Total artificial heart\nA certain percentage of patients require biventricular support with either BiVAD placement or implantation of a TAH. The 70-cc TAH (SynCardia Systems Inc., Tucson, AZ, USA) is currently the only Food and Drug Administration (FDA)-approved and Conformité Européenne (CE)-marked TAH licensed for bridge to transplant or destination therapy. However, this device is limited to patients with a larger chest cavity with adequate intrathoracic space to accommodate this device. The 50 cc-TAH (currently under investigation for FDA approval) is more appropriate for use in smaller patients, especially in complex cases who have had limited clinical options such as failing Fontan circulation [300]. Unsurprisingly, reported outcomes in patients ≤21 years supported with a TAH seem to be inferior to LVAD-only implantation [301]."}

{"project":"0_colil","denotations":[{"id":"31100109-28007058-7655","span":{"begin":714,"end":717},"obj":"28007058"},{"id":"31100109-28009714-7656","span":{"begin":844,"end":847},"obj":"28009714"}],"text":"11.4 Total artificial heart\nA certain percentage of patients require biventricular support with either BiVAD placement or implantation of a TAH. The 70-cc TAH (SynCardia Systems Inc., Tucson, AZ, USA) is currently the only Food and Drug Administration (FDA)-approved and Conformité Européenne (CE)-marked TAH licensed for bridge to transplant or destination therapy. However, this device is limited to patients with a larger chest cavity with adequate intrathoracic space to accommodate this device. The 50 cc-TAH (currently under investigation for FDA approval) is more appropriate for use in smaller patients, especially in complex cases who have had limited clinical options such as failing Fontan circulation [300]. Unsurprisingly, reported outcomes in patients ≤21 years supported with a TAH seem to be inferior to LVAD-only implantation [301]."}

{"project":"2_test","denotations":[{"id":"31100109-28007058-28905715","span":{"begin":714,"end":717},"obj":"28007058"},{"id":"31100109-28009714-28905716","span":{"begin":844,"end":847},"obj":"28009714"}],"text":"11.4 Total artificial heart\nA certain percentage of patients require biventricular support with either BiVAD placement or implantation of a TAH. The 70-cc TAH (SynCardia Systems Inc., Tucson, AZ, USA) is currently the only Food and Drug Administration (FDA)-approved and Conformité Européenne (CE)-marked TAH licensed for bridge to transplant or destination therapy. However, this device is limited to patients with a larger chest cavity with adequate intrathoracic space to accommodate this device. The 50 cc-TAH (currently under investigation for FDA approval) is more appropriate for use in smaller patients, especially in complex cases who have had limited clinical options such as failing Fontan circulation [300]. Unsurprisingly, reported outcomes in patients ≤21 years supported with a TAH seem to be inferior to LVAD-only implantation [301]."}